Inventor · disambiguated record
Matthew Howard James Campbell-Crawford
Also filed as: CAMPBELL-CRAWFORD MATTHEW HOWARD JAMES
7 granted patents·2 pending applications·31 citations·filing 2015–2019
83Inventor score
Files withGLAXOSMITHKLINE IP DEV LTD9
Top patents by PatentIndex Score
9 records- 0191US10513517B2Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseasesGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Dec 24, 2019·11 cites·3 claims
- 0284US10144733B2Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseasesGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Dec 4, 2018·5 cites·13 claims
- 0383US9956209B2Compounds αv β6 integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted May 1, 2018·4 cites·10 claims
- 0482US10000489B2Compounds αvβ6 integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Jun 19, 2018·5 cites·17 claims
- 0578US10487080B2Naphthyridines as integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted Nov 26, 2019·3 cites·23 claims
- 0676US10004724B2Compounds alpha v beta 6 integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Jun 26, 2018·2 cites·17 claims
- 0774US10342783B2Compounds αvβ6 integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Jul 9, 2019·1 cites·38 claims
- 0856US2019275016A1NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS.GLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 0943US2021206758A1Naphthyridines as integrin antagonistsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Howard James Campbell-Crawford files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →